

Pembrolizumab KEYNOTE-181

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Not qualified for an ESMO-MCBS credit



Serious and disabling adverse effects




Other adjustments



Pembrolizumab KEYNOTE-181

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gastrointestinal Cancers
Therapeutic Indication: Locally advanced or metastatic oesophageal or OGJ carcinoma that is not amenable to surgical resection or definitive CRT after ≥ 1 prior lines of systemic therapy for patients with tumours of squamous cell histology that express PD-L1 (CPS ≥ 10)
Experimental Arm: Pembrolizumab
Control Arm: Chemotherapy



